Zobrazeno 1 - 10
of 49
pro vyhledávání: '"Luis Calzadilla Bertot"'
Autor:
Luis Calzadilla-Bertot, Gary P. Jeffrey, Zhengyi Wang, Yi Huang, George Garas, Michael Wallace, Bastiaan de Boer, Jacob George, Mohammed Eslam, Amy Phu, Javier Ampuero, Ana Lucena Valera, Manuel Romero-Gómez, Rocio Aller de la Fuente, Leon A. Adams
Publikováno v:
Hepatology.
Autor:
Naga Chalasani, Luis Calzadilla-Bertot, Archita P. Desai, Mohammed Eslam, Manuel Romero-Gómez, Rocio Aller-de la Fuente, Eduardo Vilar-Gomez, Jacob George, Leon A. Adams, Vincent Wai-Sun Wong, Grace Lai-Hung Wong, Marlen Castellanos, Gary P. Jeffrey
Publikováno v:
Hepatology. 73:2238-2250
BACKGROUND AND AIMS Nonalcoholic fatty liver disease (NAFLD) is an increasingly important cause of liver cirrhosis and subsequent complications. We retrospectively developed and validated a model to predict hepatic decompensation in patients with NAF
Autor:
Luis Alberto Pérez Blanco, Eduardo Vilar Gómez, Yadina Martínez Pérez, Luis Calzadilla Bertot
Publikováno v:
Acta Gastroenterológica Latinoamericana, Vol 43, Iss 3, Pp 254-260 (2013)
Se presenta una revisión sobre la enfermedad hepática no alcohólica, teniendo en cuenta los aspectos más actuales de la fisiopatología, el diagnóstico y el tratamiento de la enfermedad.
Externí odkaz:
https://doaj.org/article/898610c0293a41c692e49d0e0ac66577
Publikováno v:
Revista Cubana de Medicina, Vol 50, Iss 2, Pp 190-201 (2011)
Los modelos pronósticos representan un pilar importante en la evaluación de los pacientes con cirrosis hepática, sobre todo a la hora de tomar decisiones como el trasplante hepático. Los 2 modelos más utilizados al nivel mundial, el Child Pugh T
Externí odkaz:
https://doaj.org/article/2dc758bc25f344459c4e90d6343461ca
Autor:
Yi Huang, Bastiaan de Boer, Briohny W. Smith, George Garas, Leon A. Adams, Zhengyi Wang, Gary P. Jeffrey, Michael C. Wallace, Luis Calzadilla Bertot, Gerry MacQuillan, John Joseph
Publikováno v:
Clinical Gastroenterology and Hepatology. 20:2041-2049.e5
Background & Aims Metabolic dysfunction–associated fatty liver disease (MAFLD) is managed predominately in primary care, however, there is uncertainty regarding how to best identify patients for specialist referral. We examined the accuracy of noni
Autor:
Luis Calzadilla Bertot
Publikováno v:
Alimentary Pharmacology & Therapeutics. 55:126-127
Autor:
Eduardo Vilar Gomez, Ana Torres Gonzalez, Luis Calzadilla Bertot, Ali Yasells Garcia, Yoan Sanchez Rodriguez, Yadina Martinez Perez
Publikováno v:
PLoS ONE, Vol 9, Iss 4, p e95736 (2014)
BACKGROUND: Arterial blood pressure (BP) is a reliable marker of circulatory dysfunction in cirrhotic patients. There are no prospective studies evaluating the association between different levels of arterial BP and ascites development in compensated
Externí odkaz:
https://doaj.org/article/7670b0ede7b342b688f97177eeeff0e7
Publikováno v:
Hepatology (Baltimore, Md.)References. 74(1)
We thank the correspondents for their interest in our study regarding the development of ABIDE, a predictive model of hepatic decompensation in non-alcoholic fatty liver disease (NAFLD) patients with cirrhosis. We have previously published outcomes i
Autor:
Leon A. Adams, Luis Calzadilla Bertot
Publikováno v:
Current Hepatology Reports. 16:356-365
Non-alcoholic fatty liver disease is the most prevalent liver disease worldwide and is associated with increased mortality risk related to cardiovascular and liver disease. We aim to review the current evidence regarding the role of exercise in non-a
Autor:
Moisés Diago, Leon A. Adams, Sacha Lazo-del Vallin, Eduardo Vilar-Gomez, Luis Calzadilla-Bertot, Scott L. Friedman, Licet Gonzalez-Fabian, Bienvenido Gra-Oramas
Publikováno v:
Liver International. 37:1887-1896
Background & Aims The dynamic response of serum fibrosis biomarkers to histological changes within the liver following lifestyle intervention (LI) is unknown. We explored relationships between changes in serum biomarkers and liver fibrosis in NASH pa